Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

“Checkpoint inhibitor resistance remains a significant challenge for patients with advanced cancer, with limited treatment options beyond chemotherapy or clinical ... solnerstotug and Libtayo ...

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced non-small ... Sequencing the novel drug, THIO, with Libtayo tended to be ...

You may take cemiplimab (Libtayo), nivolumab (Opdivo), or pembrolizumab ... rash, and joint pain. Chemo is the standard treatment when you don't have a gene change or high PD-L1.

The Nonmelanoma Skin Cancer market is expected to experience substantial growth from 2024 to 2034, driven by increasing ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

Two weeks after the Full House alum confirmed he was cancer-free following a five-month battle with stage 3 non-Hodgkin lymphoma, he shared insight into his chemotherapy treatment. “They say ...

The number of chemotherapy cycles a person needs to undergo to treat cancer can range from 4 to 8. A cycle is the length of time from the beginning of one cycle until the start of the next cycle.

In patients with gastrointestinal cancers treated with fluoropyrimidine-based chemotherapy agents, better overall survival at 1 year offsets a small increase in their risk of CV events, new data ...

Above all else, the former Full House actor discussed the painful experiences he endured amid his chemotherapy treatment, as well as his struggles to cope with the illness as his health rapidly ...